Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2024-03-21 Annual Report
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '年度报告摘要' which translates to 'Annual Report Summary' and contains detailed financial data for the year 2023, including assets, liabilities, net profit, and shareholder information. It references the full annual report and encourages investors to read the full report on the Beijing Stock Exchange website. It also includes audit information mentioning a standard unqualified opinion from Ernst & Young Hua Ming LLP, which is typical for annual reports. The document length is 7413 characters, which is substantial and contains actual financial data and company business descriptions. Therefore, this document is the Annual Report itself, not just an announcement or summary notice. Hence, the correct classification is Annual Report (10-K). FY 2023
2024-03-21 Chinese
关于召开2023年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and voted on at the AGM, such as the 2023 annual board work report, supervisory board report, annual report and its summary, financial statements, audit report, financial budget for 2024, and other related matters. It also includes procedural details for shareholders to attend and vote, proxy forms, and contact information. The document does not contain the actual annual report or financial statements but rather the notice and agenda for the AGM where these reports will be reviewed and approved. Therefore, this document fits the category of AGM Information (AGM-R).
2024-03-21 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司2023年度募集资金存放与实际使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2023 annual verification of the storage and actual use of raised funds by Beijing Kangle Weishi Biotechnology Co., Ltd. It includes extensive financial data on fundraising amounts, usage, changes in fund allocation, bank accounts for fund storage, and compliance with regulatory requirements. The document references specific regulatory approvals, fundraising events, and audit opinions from accounting firms. It is a comprehensive report on the management and use of raised capital for the fiscal year 2023, including detailed tables and explanations of fund usage and changes. This matches the definition of a Capital/Financing Update (CAP), as it focuses on fundraising activities, capital raised, and the use of those funds rather than a full annual report or audit report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to capital raising and fund usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-03-21 Chinese
北京康乐卫士生物技术股份有限公司2023年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation regarding non-operating fund occupation and other related party fund transactions for the year 2023 by Beijing Kangle Weishi Biotechnology Co., Ltd. It includes an audit report issued by Ernst & Young Hua Ming Certified Public Accountants dated March 21, 2024, with an unqualified opinion on the 2023 financial statements. The document contains detailed financial data and tables about related party transactions and fund usage, which are supplementary to the audited financial statements. This is not a full annual report but a standalone audit-related disclosure focusing on specific financial audit matters related to non-operating fund occupation and related party transactions. It is not a mere announcement or certification but contains substantive audited financial information. Therefore, it fits best under the category of Audit Report / Information (AR).
2024-03-21 Chinese
关于2023年年度权益分派的说明
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the 2023 annual equity distribution plan. It details the decision not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserves into share capital due to net losses in 2023. The document includes information about board and supervisory committee approvals, references to the company's articles of association regarding profit distribution, and commitments related to dividend policies. It explicitly states that the equity distribution plan is subject to shareholder meeting approval and includes risk warnings about the uncertainty of the plan. The document is focused on the explanation and announcement of the dividend distribution plan rather than the full annual report or financial statements. It is also relatively short (2482 characters) and does not contain comprehensive financial data or detailed financial statements. Therefore, it fits the category of a Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2024-03-21 Chinese
股权激励计划限制性股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the lifting of restrictions on certain shares under a stock incentive plan. It details the number of shares becoming unrestricted, the shareholders involved, and the reasons for lifting the restrictions. It also includes updated shareholding structure information post-lifting. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share restriction removal, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share status and capital structure. The document length is short and focused on share restriction removal, not a full report or financial disclosure.
2024-03-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.